Brian Sauer
Concepts (394)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 42 | 2024 | 1169 | 5.810 |
Why?
| | Antirheumatic Agents | 24 | 2024 | 304 | 5.320 |
Why?
| | Veterans | 32 | 2023 | 1603 | 3.710 |
Why?
| | Spondylitis, Ankylosing | 5 | 2020 | 43 | 2.360 |
Why?
| | Hyperkalemia | 3 | 2023 | 35 | 2.200 |
Why?
| | Veterans Health | 8 | 2023 | 189 | 2.080 |
Why?
| | United States Department of Veterans Affairs | 12 | 2021 | 768 | 1.840 |
Why?
| | Methotrexate | 10 | 2021 | 240 | 1.780 |
Why?
| | Spondylarthritis | 3 | 2020 | 50 | 1.240 |
Why?
| | Natural Language Processing | 4 | 2023 | 103 | 1.210 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2019 | 257 | 1.160 |
Why?
| | Rheumatology | 2 | 2020 | 133 | 1.160 |
Why?
| | Biological Products | 6 | 2021 | 252 | 1.140 |
Why?
| | Registries | 18 | 2024 | 2385 | 1.110 |
Why?
| | Tumor Necrosis Factor-alpha | 6 | 2024 | 1217 | 1.080 |
Why?
| | Medication Adherence | 4 | 2019 | 539 | 1.010 |
Why?
| | Drug Substitution | 3 | 2021 | 63 | 0.900 |
Why?
| | Psoriasis | 2 | 2015 | 112 | 0.830 |
Why?
| | Arthritis, Psoriatic | 3 | 2019 | 15 | 0.800 |
Why?
| | Lymphoma, Follicular | 2 | 2021 | 56 | 0.790 |
Why?
| | Aged | 46 | 2024 | 25913 | 0.780 |
Why?
| | Sulfasalazine | 3 | 2019 | 22 | 0.770 |
Why?
| | Misoprostol | 1 | 2022 | 15 | 0.740 |
Why?
| | Hydroxychloroquine | 3 | 2019 | 63 | 0.730 |
Why?
| | HLA-B27 Antigen | 3 | 2019 | 16 | 0.730 |
Why?
| | Lung Diseases, Interstitial | 6 | 2024 | 660 | 0.700 |
Why?
| | Humans | 97 | 2024 | 144759 | 0.690 |
Why?
| | Middle Aged | 47 | 2024 | 35875 | 0.670 |
Why?
| | Databases, Factual | 7 | 2018 | 1486 | 0.660 |
Why?
| | United States | 31 | 2023 | 15966 | 0.650 |
Why?
| | Electronic Health Records | 6 | 2023 | 1173 | 0.640 |
Why?
| | Cohort Studies | 16 | 2024 | 5960 | 0.640 |
Why?
| | Rituximab | 2 | 2021 | 209 | 0.640 |
Why?
| | Infliximab | 3 | 2016 | 108 | 0.630 |
Why?
| | Insurance Claim Review | 2 | 2017 | 83 | 0.620 |
Why?
| | Practice Patterns, Physicians' | 5 | 2019 | 1356 | 0.610 |
Why?
| | Pharmaceutical Services | 2 | 2019 | 78 | 0.610 |
Why?
| | Analgesics, Opioid | 5 | 2020 | 1143 | 0.600 |
Why?
| | Buprenorphine | 1 | 2023 | 190 | 0.590 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 338 | 0.590 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 53 | 0.580 |
Why?
| | Arthritis | 2 | 2021 | 96 | 0.580 |
Why?
| | Algorithms | 5 | 2020 | 1837 | 0.580 |
Why?
| | Datasets as Topic | 1 | 2019 | 122 | 0.570 |
Why?
| | Treatment Outcome | 19 | 2024 | 11679 | 0.560 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2019 | 62 | 0.560 |
Why?
| | Severity of Illness Index | 12 | 2023 | 2925 | 0.550 |
Why?
| | Etanercept | 2 | 2016 | 60 | 0.550 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 199 | 0.540 |
Why?
| | Adalimumab | 2 | 2016 | 55 | 0.540 |
Why?
| | Male | 54 | 2024 | 72315 | 0.540 |
Why?
| | Iron | 2 | 2021 | 359 | 0.520 |
Why?
| | Kidney Failure, Chronic | 1 | 2022 | 598 | 0.490 |
Why?
| | Chronic Pain | 3 | 2022 | 290 | 0.480 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2021 | 653 | 0.480 |
Why?
| | Computer Simulation | 4 | 2020 | 1025 | 0.470 |
Why?
| | Drug Monitoring | 4 | 2012 | 395 | 0.460 |
Why?
| | Female | 49 | 2024 | 78271 | 0.460 |
Why?
| | Delivery of Health Care | 2 | 2022 | 947 | 0.460 |
Why?
| | Terminology as Topic | 1 | 2017 | 255 | 0.450 |
Why?
| | Healthcare Common Procedure Coding System | 1 | 2014 | 1 | 0.440 |
Why?
| | Cross-Over Studies | 1 | 2017 | 601 | 0.440 |
Why?
| | Diabetes Mellitus | 3 | 2024 | 1098 | 0.430 |
Why?
| | Opioid-Related Disorders | 1 | 2023 | 600 | 0.430 |
Why?
| | Risk Factors | 23 | 2024 | 10779 | 0.430 |
Why?
| | Polymers | 3 | 2023 | 499 | 0.430 |
Why?
| | Research Design | 3 | 2020 | 1135 | 0.420 |
Why?
| | Insurance, Pharmaceutical Services | 2 | 2011 | 24 | 0.420 |
Why?
| | Adipokines | 3 | 2022 | 57 | 0.410 |
Why?
| | Cytokines | 5 | 2024 | 2061 | 0.410 |
Why?
| | Narcotics | 1 | 2013 | 55 | 0.390 |
Why?
| | Models, Statistical | 2 | 2017 | 681 | 0.390 |
Why?
| | Hospitalization | 5 | 2021 | 2433 | 0.370 |
Why?
| | Ambulatory Care | 2 | 2014 | 600 | 0.370 |
Why?
| | Potassium | 2 | 2023 | 152 | 0.370 |
Why?
| | Utah | 7 | 2013 | 81 | 0.370 |
Why?
| | Comparative Effectiveness Research | 1 | 2013 | 170 | 0.370 |
Why?
| | Pharmaceutical Preparations | 3 | 2022 | 170 | 0.360 |
Why?
| | Drug Prescriptions | 2 | 2013 | 284 | 0.360 |
Why?
| | Remission Induction | 3 | 2022 | 307 | 0.360 |
Why?
| | Medicine | 1 | 2013 | 125 | 0.350 |
Why?
| | Emergency Service, Hospital | 3 | 2023 | 2310 | 0.350 |
Why?
| | Time Factors | 11 | 2021 | 7173 | 0.340 |
Why?
| | Carpal Bones | 2 | 2021 | 17 | 0.340 |
Why?
| | Drug Overdose | 2 | 2012 | 370 | 0.340 |
Why?
| | Proportional Hazards Models | 8 | 2022 | 1325 | 0.330 |
Why?
| | Decision Support Systems, Clinical | 2 | 2012 | 265 | 0.320 |
Why?
| | Cardiovascular Diseases | 8 | 2023 | 2168 | 0.320 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2015 | 365 | 0.320 |
Why?
| | Disease Progression | 2 | 2018 | 2847 | 0.320 |
Why?
| | Health Services Accessibility | 2 | 2019 | 1098 | 0.310 |
Why?
| | Potentially Inappropriate Medication List | 2 | 2020 | 16 | 0.310 |
Why?
| | Adiponectin | 4 | 2024 | 244 | 0.310 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1560 | 0.310 |
Why?
| | Quality Indicators, Health Care | 1 | 2012 | 335 | 0.300 |
Why?
| | C-Reactive Protein | 4 | 2021 | 416 | 0.300 |
Why?
| | Retrospective Studies | 18 | 2023 | 17066 | 0.300 |
Why?
| | Risk Assessment | 10 | 2021 | 3671 | 0.270 |
Why?
| | Kaplan-Meier Estimate | 3 | 2021 | 965 | 0.270 |
Why?
| | Aged, 80 and over | 13 | 2021 | 8265 | 0.270 |
Why?
| | Body Mass Index | 6 | 2018 | 2438 | 0.270 |
Why?
| | Incidence | 9 | 2024 | 2879 | 0.260 |
Why?
| | Pneumonia, Bacterial | 2 | 2020 | 113 | 0.260 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 1519 | 0.260 |
Why?
| | Prospective Studies | 9 | 2024 | 7990 | 0.260 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2013 | 1414 | 0.260 |
Why?
| | ROC Curve | 3 | 2019 | 614 | 0.250 |
Why?
| | International Classification of Diseases | 4 | 2023 | 147 | 0.250 |
Why?
| | Arthrodesis | 3 | 2021 | 35 | 0.240 |
Why?
| | Managed Care Programs | 1 | 2007 | 138 | 0.240 |
Why?
| | Multimorbidity | 2 | 2023 | 63 | 0.240 |
Why?
| | Predictive Value of Tests | 4 | 2020 | 2115 | 0.230 |
Why?
| | Drug Utilization | 2 | 2018 | 166 | 0.230 |
Why?
| | Drug Therapy, Combination | 2 | 2019 | 1047 | 0.220 |
Why?
| | Propensity Score | 3 | 2020 | 367 | 0.220 |
Why?
| | Embryo, Nonmammalian | 2 | 2005 | 173 | 0.220 |
Why?
| | Patient Admission | 1 | 2007 | 218 | 0.220 |
Why?
| | Gene Targeting | 1 | 2004 | 82 | 0.210 |
Why?
| | Data Mining | 3 | 2023 | 117 | 0.210 |
Why?
| | Alarmins | 1 | 2024 | 27 | 0.210 |
Why?
| | Interleukin-33 | 1 | 2024 | 45 | 0.210 |
Why?
| | Regression Analysis | 3 | 2018 | 1003 | 0.210 |
Why?
| | Adult | 16 | 2022 | 40449 | 0.200 |
Why?
| | Embryo, Mammalian | 1 | 2004 | 232 | 0.200 |
Why?
| | Wrist | 2 | 2021 | 60 | 0.200 |
Why?
| | Wrist Joint | 2 | 2021 | 71 | 0.200 |
Why?
| | Poisson Distribution | 2 | 2017 | 78 | 0.200 |
Why?
| | Polystyrenes | 1 | 2023 | 37 | 0.190 |
Why?
| | Neurology | 1 | 2024 | 112 | 0.190 |
Why?
| | Diclofenac | 1 | 2022 | 14 | 0.180 |
Why?
| | Follow-Up Studies | 7 | 2021 | 5408 | 0.180 |
Why?
| | Weight Loss | 2 | 2018 | 836 | 0.180 |
Why?
| | Neoplasms | 5 | 2023 | 2875 | 0.180 |
Why?
| | Chemokines | 2 | 2021 | 218 | 0.180 |
Why?
| | Blood Sedimentation | 2 | 2019 | 37 | 0.180 |
Why?
| | Comorbidity | 4 | 2023 | 1658 | 0.180 |
Why?
| | Research Report | 1 | 2022 | 87 | 0.180 |
Why?
| | Stroke | 2 | 2021 | 1256 | 0.180 |
Why?
| | Rheumatic Diseases | 1 | 2023 | 97 | 0.180 |
Why?
| | Confidence Intervals | 2 | 2016 | 333 | 0.180 |
Why?
| | Genetic Testing | 1 | 2004 | 478 | 0.170 |
Why?
| | Polymerase Chain Reaction | 1 | 2004 | 1054 | 0.170 |
Why?
| | Linear Models | 3 | 2018 | 854 | 0.170 |
Why?
| | Multivariate Analysis | 5 | 2018 | 1539 | 0.170 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2021 | 19 | 0.170 |
Why?
| | Hospitals, Veterans | 3 | 2018 | 259 | 0.170 |
Why?
| | Education, Medical | 1 | 2024 | 274 | 0.160 |
Why?
| | Maintenance Chemotherapy | 1 | 2020 | 42 | 0.160 |
Why?
| | Prescription Drugs | 2 | 2012 | 111 | 0.160 |
Why?
| | Cyclophosphamide | 2 | 2021 | 266 | 0.160 |
Why?
| | Communication | 2 | 2024 | 965 | 0.160 |
Why?
| | Arthritis, Infectious | 1 | 2021 | 72 | 0.160 |
Why?
| | Stem Cells | 1 | 2004 | 626 | 0.160 |
Why?
| | Prosthesis-Related Infections | 1 | 2021 | 99 | 0.150 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2020 | 27 | 0.150 |
Why?
| | Neoplasm Grading | 1 | 2020 | 307 | 0.150 |
Why?
| | SEER Program | 1 | 2020 | 224 | 0.150 |
Why?
| | Transferrin | 1 | 2019 | 50 | 0.150 |
Why?
| | Ferritins | 1 | 2019 | 69 | 0.150 |
Why?
| | Ranolazine | 1 | 2018 | 25 | 0.140 |
Why?
| | Inappropriate Prescribing | 1 | 2019 | 63 | 0.140 |
Why?
| | Bipolar Disorder | 1 | 2021 | 280 | 0.140 |
Why?
| | Angina, Stable | 1 | 2018 | 18 | 0.140 |
Why?
| | Area Under Curve | 1 | 2019 | 330 | 0.140 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2021 | 182 | 0.140 |
Why?
| | Geriatrics | 1 | 2019 | 96 | 0.140 |
Why?
| | Coronary Artery Disease | 2 | 2022 | 741 | 0.140 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 192 | 0.140 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2020 | 248 | 0.130 |
Why?
| | Professional Practice Location | 1 | 2017 | 26 | 0.130 |
Why?
| | Rheumatologists | 1 | 2017 | 15 | 0.130 |
Why?
| | Osteoarthritis | 1 | 2020 | 196 | 0.130 |
Why?
| | Random Allocation | 1 | 2018 | 363 | 0.130 |
Why?
| | Anti-Citrullinated Protein Antibodies | 1 | 2019 | 126 | 0.130 |
Why?
| | Sacroiliitis | 1 | 2017 | 7 | 0.130 |
Why?
| | Calcium Channel Blockers | 1 | 2018 | 165 | 0.130 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2018 | 87 | 0.130 |
Why?
| | Heart Failure | 2 | 2021 | 2323 | 0.130 |
Why?
| | Brain Ischemia | 1 | 2021 | 358 | 0.130 |
Why?
| | Obesity, Abdominal | 1 | 2017 | 46 | 0.130 |
Why?
| | Longitudinal Studies | 4 | 2023 | 2947 | 0.130 |
Why?
| | Protease Inhibitors | 1 | 2018 | 102 | 0.130 |
Why?
| | Bias | 3 | 2013 | 202 | 0.130 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2018 | 250 | 0.130 |
Why?
| | Data Accuracy | 1 | 2017 | 65 | 0.130 |
Why?
| | Population Surveillance | 2 | 2012 | 485 | 0.130 |
Why?
| | Neoplasm Metastasis | 1 | 2019 | 688 | 0.130 |
Why?
| | Disability Evaluation | 1 | 2018 | 310 | 0.130 |
Why?
| | Risk Management | 2 | 2007 | 84 | 0.130 |
Why?
| | Recovery of Function | 1 | 2021 | 707 | 0.130 |
Why?
| | HIV Integrase Inhibitors | 1 | 2018 | 78 | 0.120 |
Why?
| | Feasibility Studies | 2 | 2020 | 1095 | 0.120 |
Why?
| | Leptin | 3 | 2022 | 245 | 0.120 |
Why?
| | Pain | 1 | 2022 | 779 | 0.120 |
Why?
| | Adverse Drug Reaction Reporting Systems | 2 | 2007 | 81 | 0.120 |
Why?
| | Forecasting | 1 | 2018 | 391 | 0.120 |
Why?
| | Travel | 1 | 2017 | 136 | 0.120 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2016 | 140 | 0.120 |
Why?
| | Precision Medicine | 1 | 2020 | 457 | 0.120 |
Why?
| | Prognosis | 3 | 2020 | 4282 | 0.120 |
Why?
| | Neoplasm Staging | 1 | 2020 | 1462 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 2 | 2018 | 474 | 0.120 |
Why?
| | Hypertension | 2 | 2018 | 1263 | 0.120 |
Why?
| | Antimicrobial Stewardship | 1 | 2018 | 129 | 0.120 |
Why?
| | Fees, Pharmaceutical | 1 | 2015 | 8 | 0.120 |
Why?
| | Drug Administration Routes | 1 | 2015 | 42 | 0.120 |
Why?
| | Observational Studies as Topic | 1 | 2016 | 129 | 0.120 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2021 | 370 | 0.120 |
Why?
| | Anti-Infective Agents | 1 | 2018 | 242 | 0.110 |
Why?
| | Anti-Retroviral Agents | 1 | 2018 | 250 | 0.110 |
Why?
| | Cross-Sectional Studies | 6 | 2024 | 5868 | 0.110 |
Why?
| | Cyclosporine | 1 | 2016 | 265 | 0.110 |
Why?
| | Hospital Mortality | 1 | 2020 | 1030 | 0.110 |
Why?
| | Pseudomonas Infections | 1 | 2017 | 221 | 0.110 |
Why?
| | Cause of Death | 4 | 2023 | 471 | 0.110 |
Why?
| | Logistic Models | 2 | 2018 | 2117 | 0.110 |
Why?
| | Recombination, Genetic | 3 | 2005 | 205 | 0.110 |
Why?
| | Health Care Costs | 1 | 2018 | 427 | 0.110 |
Why?
| | Inflammation Mediators | 1 | 2017 | 509 | 0.110 |
Why?
| | Obesity | 2 | 2018 | 3077 | 0.110 |
Why?
| | Cross Infection | 1 | 2017 | 262 | 0.110 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 779 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2018 | 535 | 0.100 |
Why?
| | Suicide | 1 | 2021 | 720 | 0.100 |
Why?
| | Health Expenditures | 1 | 2015 | 194 | 0.100 |
Why?
| | Guideline Adherence | 1 | 2018 | 589 | 0.100 |
Why?
| | Quality Improvement | 1 | 2022 | 1289 | 0.100 |
Why?
| | Infusions, Intravenous | 1 | 2014 | 423 | 0.100 |
Why?
| | Prednisone | 3 | 2021 | 221 | 0.100 |
Why?
| | Causality | 1 | 2013 | 126 | 0.100 |
Why?
| | Integrases | 3 | 2005 | 122 | 0.100 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2012 | 40 | 0.090 |
Why?
| | Adiposity | 1 | 2017 | 543 | 0.090 |
Why?
| | Telemedicine | 1 | 2022 | 945 | 0.090 |
Why?
| | Education, Medical, Continuing | 1 | 2013 | 132 | 0.090 |
Why?
| | Root Cause Analysis | 1 | 2012 | 9 | 0.090 |
Why?
| | Socioeconomic Factors | 2 | 2018 | 1326 | 0.090 |
Why?
| | Pneumonia | 1 | 2018 | 631 | 0.090 |
Why?
| | Mortality | 1 | 2015 | 375 | 0.090 |
Why?
| | HIV Infections | 2 | 2018 | 3154 | 0.090 |
Why?
| | Feedback | 2 | 2023 | 181 | 0.090 |
Why?
| | Occupational Injuries | 1 | 2012 | 46 | 0.090 |
Why?
| | Prescription Drug Misuse | 1 | 2012 | 51 | 0.090 |
Why?
| | Florida | 1 | 2012 | 117 | 0.090 |
Why?
| | Lung Diseases | 1 | 2018 | 787 | 0.090 |
Why?
| | HIV-1 | 1 | 2018 | 896 | 0.090 |
Why?
| | Lung Neoplasms | 2 | 2022 | 2637 | 0.090 |
Why?
| | Narration | 1 | 2012 | 75 | 0.080 |
Why?
| | Osteoporotic Fractures | 1 | 2012 | 61 | 0.080 |
Why?
| | Outpatients | 1 | 2014 | 442 | 0.080 |
Why?
| | Health Personnel | 1 | 2017 | 748 | 0.080 |
Why?
| | Risk | 1 | 2013 | 911 | 0.080 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2194 | 0.080 |
Why?
| | Internal Medicine | 1 | 2013 | 280 | 0.080 |
Why?
| | Adolescent | 5 | 2015 | 22428 | 0.080 |
Why?
| | Reproducibility of Results | 2 | 2016 | 3409 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2027 | 0.080 |
Why?
| | Substance-Related Disorders | 2 | 2023 | 1094 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1907 | 0.070 |
Why?
| | Blood Pressure | 2 | 2018 | 1769 | 0.070 |
Why?
| | Young Adult | 3 | 2015 | 14105 | 0.070 |
Why?
| | Pattern Recognition, Automated | 1 | 2008 | 74 | 0.070 |
Why?
| | Sex Factors | 3 | 2021 | 2112 | 0.070 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2008 | 91 | 0.070 |
Why?
| | Hospital Records | 1 | 2007 | 10 | 0.070 |
Why?
| | Financing, Personal | 1 | 2007 | 27 | 0.070 |
Why?
| | Catheter-Related Infections | 1 | 2008 | 94 | 0.070 |
Why?
| | Cost Sharing | 1 | 2007 | 20 | 0.070 |
Why?
| | Antihypertensive Agents | 1 | 2011 | 510 | 0.060 |
Why?
| | Nonlinear Dynamics | 1 | 2007 | 95 | 0.060 |
Why?
| | Referral and Consultation | 1 | 2013 | 851 | 0.060 |
Why?
| | Biomarkers | 3 | 2024 | 4271 | 0.060 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2005 | 381 | 0.060 |
Why?
| | Insulin-Like Growth Factor I | 2 | 1999 | 319 | 0.060 |
Why?
| | Viral Proteins | 2 | 1999 | 355 | 0.060 |
Why?
| | Machine Learning | 2 | 2022 | 585 | 0.060 |
Why?
| | Primary Health Care | 2 | 2013 | 1733 | 0.060 |
Why?
| | Drug Interactions | 1 | 2007 | 398 | 0.060 |
Why?
| | Respiratory Tract Diseases | 2 | 2017 | 175 | 0.060 |
Why?
| | Models, Theoretical | 1 | 2008 | 582 | 0.050 |
Why?
| | Health Services Research | 1 | 2007 | 396 | 0.050 |
Why?
| | Data Collection | 1 | 2007 | 633 | 0.050 |
Why?
| | Blotting, Southern | 1 | 2004 | 85 | 0.050 |
Why?
| | Chronic Disease | 2 | 2022 | 1813 | 0.050 |
Why?
| | Inpatients | 2 | 2024 | 545 | 0.050 |
Why?
| | Artificial Intelligence | 1 | 2008 | 365 | 0.050 |
Why?
| | Interleukin-17 | 1 | 2024 | 118 | 0.050 |
Why?
| | Myocardial Infarction | 1 | 2011 | 1209 | 0.050 |
Why?
| | Mental Disorders | 1 | 2012 | 1168 | 0.050 |
Why?
| | Mass Screening | 1 | 2012 | 1347 | 0.050 |
Why?
| | Vital Capacity | 1 | 2023 | 290 | 0.050 |
Why?
| | Health Status | 2 | 2018 | 836 | 0.050 |
Why?
| | Odds Ratio | 2 | 2018 | 1075 | 0.050 |
Why?
| | Acetazolamide | 1 | 2022 | 26 | 0.050 |
Why?
| | Telomere Shortening | 1 | 2022 | 19 | 0.050 |
Why?
| | Antimanic Agents | 1 | 2021 | 19 | 0.040 |
Why?
| | Lithium | 1 | 2021 | 42 | 0.040 |
Why?
| | Valproic Acid | 1 | 2021 | 47 | 0.040 |
Why?
| | Medicare | 1 | 2007 | 886 | 0.040 |
Why?
| | Length of Stay | 1 | 2007 | 1337 | 0.040 |
Why?
| | Medication Therapy Management | 1 | 2022 | 73 | 0.040 |
Why?
| | Chlorambucil | 1 | 2021 | 10 | 0.040 |
Why?
| | Vidarabine | 1 | 2021 | 32 | 0.040 |
Why?
| | Bendamustine Hydrochloride | 1 | 2021 | 17 | 0.040 |
Why?
| | Bortezomib | 1 | 2021 | 55 | 0.040 |
Why?
| | Pulmonologists | 1 | 2020 | 14 | 0.040 |
Why?
| | Patient Discharge | 2 | 2023 | 983 | 0.040 |
Why?
| | Zebrafish | 1 | 2005 | 528 | 0.040 |
Why?
| | Data Display | 1 | 2020 | 20 | 0.040 |
Why?
| | Vincristine | 1 | 2021 | 140 | 0.040 |
Why?
| | Quality Control | 1 | 2020 | 163 | 0.040 |
Why?
| | Computed Tomography Angiography | 1 | 2021 | 145 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2022 | 280 | 0.040 |
Why?
| | Pharmacists | 1 | 2022 | 240 | 0.040 |
Why?
| | User-Computer Interface | 1 | 2020 | 164 | 0.040 |
Why?
| | Embryonic and Fetal Development | 1 | 1999 | 93 | 0.040 |
Why?
| | Bone Marrow Transplantation | 1 | 2020 | 294 | 0.040 |
Why?
| | Range of Motion, Articular | 1 | 2021 | 421 | 0.040 |
Why?
| | Piperidines | 1 | 2021 | 217 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2022 | 3863 | 0.040 |
Why?
| | Magnetic Resonance Angiography | 1 | 2021 | 251 | 0.040 |
Why?
| | Telomere | 1 | 2022 | 288 | 0.040 |
Why?
| | Dexamethasone | 1 | 2021 | 372 | 0.040 |
Why?
| | Doxorubicin | 1 | 2021 | 397 | 0.040 |
Why?
| | Adenine | 1 | 2021 | 339 | 0.030 |
Why?
| | Gene Dosage | 1 | 1998 | 148 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2022 | 704 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 634 | 0.030 |
Why?
| | Methicillin Resistance | 1 | 2017 | 17 | 0.030 |
Why?
| | Infant Mortality | 1 | 1998 | 123 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2019 | 243 | 0.030 |
Why?
| | Recurrence | 1 | 2020 | 1135 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 1999 | 905 | 0.030 |
Why?
| | Reoperation | 1 | 2020 | 630 | 0.030 |
Why?
| | HIV Integrase | 1 | 2018 | 74 | 0.030 |
Why?
| | Rheumatic Nodule | 1 | 2016 | 3 | 0.030 |
Why?
| | Cardiovascular Agents | 1 | 2018 | 164 | 0.030 |
Why?
| | Absorptiometry, Photon | 1 | 2017 | 276 | 0.030 |
Why?
| | Isoxazoles | 1 | 2016 | 53 | 0.030 |
Why?
| | Thinness | 1 | 2016 | 99 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2017 | 282 | 0.030 |
Why?
| | Body Weight | 2 | 2016 | 976 | 0.030 |
Why?
| | Critical Illness | 1 | 2022 | 891 | 0.030 |
Why?
| | Rheumatoid Factor | 1 | 2016 | 175 | 0.030 |
Why?
| | Viral Load | 1 | 2018 | 526 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1382 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2017 | 174 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2018 | 1306 | 0.030 |
Why?
| | Lymphoma | 1 | 2016 | 232 | 0.030 |
Why?
| | Peptides, Cyclic | 1 | 2016 | 275 | 0.030 |
Why?
| | Leukemia | 1 | 2016 | 245 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 6048 | 0.030 |
Why?
| | Life Style | 1 | 2016 | 479 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2018 | 691 | 0.020 |
Why?
| | Age Factors | 1 | 2021 | 3333 | 0.020 |
Why?
| | Workers' Compensation | 1 | 2012 | 28 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 2730 | 0.020 |
Why?
| | Coroners and Medical Examiners | 1 | 2011 | 8 | 0.020 |
Why?
| | Sampling Studies | 1 | 2011 | 99 | 0.020 |
Why?
| | Death Certificates | 1 | 2011 | 32 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2878 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1953 | 0.020 |
Why?
| | Brain | 1 | 2022 | 2933 | 0.020 |
Why?
| | Smoking | 1 | 2016 | 1472 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2016 | 974 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2016 | 919 | 0.020 |
Why?
| | Medical Assistance | 1 | 2007 | 13 | 0.020 |
Why?
| | Models, Econometric | 1 | 2007 | 34 | 0.020 |
Why?
| | Psychoses, Substance-Induced | 1 | 2007 | 15 | 0.020 |
Why?
| | Deductibles and Coinsurance | 1 | 2007 | 12 | 0.020 |
Why?
| | Eligibility Determination | 1 | 2007 | 68 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 732 | 0.020 |
Why?
| | Quality of Life | 1 | 2019 | 3185 | 0.020 |
Why?
| | Costs and Cost Analysis | 1 | 2007 | 219 | 0.020 |
Why?
| | Child | 1 | 2007 | 22633 | 0.020 |
Why?
| | Delirium | 1 | 2007 | 104 | 0.010 |
Why?
| | Insurance Coverage | 1 | 2007 | 239 | 0.010 |
Why?
| | beta-Galactosidase | 1 | 2005 | 77 | 0.010 |
Why?
| | Blood Coagulation Disorders | 1 | 2007 | 189 | 0.010 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2005 | 76 | 0.010 |
Why?
| | Mosaicism | 1 | 2005 | 73 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2005 | 275 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 250 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1985 | 0.010 |
Why?
| | Mice, Transgenic | 2 | 1999 | 2182 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2011 | 3604 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2005 | 675 | 0.010 |
Why?
| | Hemorrhage | 1 | 2007 | 809 | 0.010 |
Why?
| | Liver | 2 | 1999 | 1887 | 0.010 |
Why?
| | Growth Disorders | 1 | 1998 | 86 | 0.010 |
Why?
| | Animals | 3 | 2005 | 38058 | 0.010 |
Why?
| | Mice | 2 | 1999 | 18339 | 0.010 |
Why?
| | RNA, Messenger | 1 | 1998 | 2832 | 0.000 |
Why?
| | Infant, Newborn | 1 | 1998 | 6429 | 0.000 |
Why?
|
|
Sauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|